Centogene N.V. (CNTG)

0.4610 -0.0100 (-2.12%) At close: 04:00PM EDT

Centogene N.V.

Am Strande 7
Rostock 18055
Germany
49 381 80113 500
https://www.centogene.com

Sector(s): Healthcare
Industry: Diagnostics & Research
Full Time Employees: 444

Key Executives

Name	Title	Pay	Exercised	Year Born
Ms. Kim Stratton	CEO & Member of Management Board	918.58k	N/A	1962
Mr. Jose Miguel Coego Rios	CFO, Legal & IT and Member of Management Board	319k	N/A	N/A
Dr. Peter Bauer M.D.	Chief Medical & Genomic Officer and Member of Management Board	183.5k	N/A	1970
Dr. Andrin Oswald M.D., Ph.D.	Advisor	929.25k	N/A	1972
Mr. Ian Rentsch	Chief Commercial Officer & GM of Pharma	N/A	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Centogene N.V., together with its subsidiaries, engages in the research and development of products for human genetics in Europe, the Middle East, North America, Latin America, and the Asia Pacific. It provides data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. It operates through two segments: Pharmaceutical and Diagnostics. The company provides target and drug screening, clinical development, market access and expansion, as well as CENTOGENE Biodatabank licenses and insight report services. In addition, it offers various services, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.

Corporate Governance

Centogene N.V.’s ISS Governance QualityScore as of April 1, 2024 is 7. The pillar scores are Audit: 4; Board: 6; Shareholder Rights: 5; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.